FR
about us
Leadership
Board of directors
Investors
technology
Precision delivery
Gut Restricted
PDE4
pipeline
IBD-indication
Pipeline
A word on DHC
news
contact
FR
On February 24, 2023
Giiant Pharma Receives Financial Support From the US Crohn’s and Colitis Foundation
Read more
On September 8, 2021
Giiant Pharma Inc. appoints Christophe Mellon, PhD as Vice President, Discovery & Chemistry
Read more
On June 30, 2021
Giiant Pharma Inc. extended its Seed round with AQC Capital and CQDM to ensure reaching clinical proof-of-concept
Read more
On June 17, 2021
Giiant Pharma Inc. strengthens its Board of Directors with the appointment of Dr. Marie Lindner
Read more
On May 19, 2021
Giiant Pharma Inc. announced the closing of US$11M in Seed financing to develop its Precision Delivery technology platform in gastroenterology.
Read more
recent
news
February 24, 2023
Giiant Pharma Receives Financial Support From the US Crohn’s and Colitis Foundation
Read more
September 8, 2021
Giiant Pharma Inc. appoints Christophe Mellon, PhD as Vice President, Discovery & Chemistry
Read more
June 30, 2021
Giiant Pharma Inc. extended its Seed round with AQC Capital and CQDM to ensure reaching clinical proof-of-concept
Read more
load more news
